A 484954 - CAS 142557-61-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C13H15N5O3
Molecular Weight:
289.29
COA:
Inquire
Targets:
Others
Description:
A 484954 is a eukaryotic elongation factor-2 (eEF-2) kinase inhibitor (IC50 = 0.28 μM in enzymatic assay). A 484954 reduces eEF-2 phosphorylation with little effect on cancer cell growth.
Brife Description:
eEF-2 kinase inhibitor
Purity:
≥98% by HPLC
Synonyms:
A-484954; 7-Amino-1-cyclopropyl-3-ethyl-1,2,3,4-tetrahydro-2,4-dioxopyrido[2,3-d]pyrimidine-6-carboxamide
MSDS:
Inquire
InChIKey:
HWODCHXORCTEGU-UHFFFAOYSA-N
InChI:
InChI=1S/C13H15N5O3/c1-2-17-12(20)8-5-7(10(15)19)9(14)16-11(8)18(13(17)21)6-3-4-6/h5-6H,2-4H2,1H3,(H2,14,16)(H2,15,19)
Canonical SMILES:
CCN1C(=O)C2=CC(=C(N=C2N(C1=O)C3CC3)N)C(=O)N
1.Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells.
Usui T;Nijima R;Sakatsume T;Otani K;Kameshima S;Okada M;Yamawaki H Acta Physiol (Oxf). 2015 Feb;213(2):472-80. doi: 10.1111/apha.12354. Epub 2014 Aug 26.
AIM: ;Eukaryotic elongation factor 2 kinase (eEF2K), also known as calmodulin (CaM)-dependent protein kinase (CaMK) III, is a unique member of CaMK family protein. We have recently found that expression of eEF2K protein increased in mesenteric artery from spontaneously hypertensive rats. As pathogenesis of hypertension is in part regulated by vascular structural remodelling via proliferation and migration of vascular smooth muscle cells (SMCs), we tested the hypothesis that eEF2K controls SMCs proliferation and migration.;METHODSAND RESULTS: ;In rat mesenteric arterial SMCs, an eEF2K inhibitor, A-484954 (10 μm), significantly inhibited platelet-derived growth factor (PDGF)-BB (10 ng mL(-1) )-induced SMCs proliferation as determined by a cell counting and bromodeoxyuridine incorporation assay. PDGF-BB (10 ng mL(-1) )-induced SMCs migration was significantly inhibited by A-484954 (10 μm) as determined by a Boyden chamber assay. A-484954 (10 μm) significantly inhibited PDGF-BB (10 ng mL(-1) )-induced phosphorylation of eEF2K, extracellular signal-regulated kinase (ERK), Akt, p38 and heat-shock protein (HSP) 27 as determined by Western blotting. It was confirmed that a CaM inhibitor, W-7 (50 μm), inhibited PDGF-BB (10 ng mL(-1) )-induced phosphorylation of eEF2K.
2.1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.
Chen Z;Gopalakrishnan SM;Bui MH;Soni NB;Warrior U;Johnson EF;Donnelly JB;Glaser KB J Biol Chem. 2011 Dec 23;286(51):43951-8. doi: 10.1074/jbc.M111.301291. Epub 2011 Oct 21.
Eukaryotic elongation factor-2 kinase (eEF2K) relays growth and stress signals to protein synthesis through phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2). 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) is a widely accepted inhibitor of mammalian eEF2K and an efficacious anti-proliferation agent against different cancer cells. It implied that eEF2K could be an efficacious anticancer target. However, eEF2K siRNA was ineffective against cancer cells including those sensitive to NH125. To test if pharmacological intervention differs from siRNA interference, we identified a highly selective small molecule eEF2K inhibitor A-484954. Like siRNA, A-484954 had little effect on cancer cell growth. We carefully examined the effect of NH125 and A-484954 on phosphorylation of eEF2, the known cellular substrate of eEF2K. Surprisingly, NH125 increased eEF2 phosphorylation, whereas A-484954 inhibited the phosphorylation as expected for an eEF2K inhibitor. Both A-484954 and eEF2K siRNA inhibited eEF2K and reduced eEF2 phosphorylation with little effect on cancer cell growth. These data demonstrated clearly that the anticancer activity of NH125 was more correlated with induction of eEF2 phosphorylation than inhibition of eEF2K.
3.Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling.
Kameshima S;Kazama K;Okada M;Yamawaki H Am J Physiol Heart Circ Physiol. 2015 May 15;308(10):H1298-305. doi: 10.1152/ajpheart.00864.2014. Epub 2015 Mar 13.
Pulmonary arterial (PA) hypertension (PAH) is a progressive and lethal disease that is caused by increased vascular contractile reactivity and structural remodeling. These changes contribute to increasing pulmonary peripheral vascular resistance, finally leading to right heart failure and death. Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca(2+)/calmodulin-dependent protein kinase. We previously revealed that eEF2K protein increases in the mesenteric artery from spontaneously hypertensive rats and partly mediates the development of hypertension via a promotion of ROS-dependent vascular inflammatory responses and proliferation and migration of vascular smooth muscle cells. However, a role of eEF2K in the pathogenesis of PAH is unknown. In the present study, we tested the hypothesis that eEF2K may be involved in the pathogenesis of PAH. PAH was induced by a single intraperitoneal injection of monocrotaline (MCT; 60 mg/kg) to rats. A specific eEF2K inhibitor, A-484954 (2.5 mg·kg(-1)·day(-1)), was intraperitoneally injected for 14 days. Long-term A-484954 treatment inhibited MCT-induced increased PA pressure. It was revealed that A-484954 inhibited MCT-induced PA hypertrophy and fibrosis but not impairment of endothelium-dependent and -independent relaxation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 217461-40-0 (±)-J 113397

(±)-J 113397
(CAS: 217461-40-0)

(+/-)-J 113397 has been found to be a NOP receptor antagonist and could restrain nociceptin/orphanin FQ-induced hyperalgesia in the mouse tail-flick test.

CAS 5041-82-7 Isorhamnetin-3-O-beta-D-Glucosid

Isorhamnetin-3-O-beta-D-Glucosid
(CAS: 5041-82-7)

Isorhamnetin-3-O-beta-D-Glucoside from S. herbacea is a leading compound for further study as a new drug for the prevention and/or treatment of diabetes and its...

CAS 106740-09-4 GYY-4137 Morpholine salt

GYY-4137 Morpholine salt
(CAS: 106740-09-4)

GYY-4137 Morpholine salt is a novel water-soluble and slow releasing Hydrogen sulfide(H2S) donor. It protects against myocardial ischemia and reperfusion injury...

CW 008
(CAS: 1134613-19-6)

This active molecular is a cAMP/PKA/CREB pathway activator promoting osteogenic differentiation of human bone marrow derived MSCs in vitro, and it also increase...

GLPG-1690
(CAS: 1628260-79-6)

GLPG-1690, an imidazopyridine derivative, has been found to be a ENPP2 protein inhibitor that could probably be effective as an anti-inflammatory agent and is u...

CAS 14028-44-5 Amoxapine

Amoxapine
(CAS: 14028-44-5)

Amoxapine is a tricyclic dibenzoxazepine (an N-aryl piperazine) which acts similarly to several other tricyclic antidepressants, amoxapine inhibits GLYT2a trans...

CAS 141993-70-6 Eldacimibe

Eldacimibe
(CAS: 141993-70-6)

Eldacimibe is a Sterol O-acyltransferase inhibitor originated by Wyeth. No development was reported for Atherosclerosis and Hypercholesterolaemia in USA.

CAS 297730-17-7 AVN-944

AVN-944
(CAS: 297730-17-7)

AVN-944 (VX-944) is an orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (...

Chemical Structure

CAS 142557-61-7 A 484954

Quick Inquiry

Verification code

Featured Items